Does Rallies track congressional trades in GSK?

Yes. Rallies tracks politician and congressional stock disclosures for GSK, including reported purchases, sales, dates, owners, and trade amounts when available.

Is GSK research on Rallies investment advice?

No. Rallies provides research, data, and educational context for GSK. It does not provide personalized investment advice.

GSK (GSK plc American Depositary Shares (Each representing two Ordinary Shares)) Stock Analysis - Politician Trades

GSK plc American Depositary Shares (Each representing two Ordinary Shares) (GSK) is a publicly traded Healthcare sector company. As of May 20, 2026, GSK trades at $50.83 with a market cap of $100.90B and a P/E ratio of 0.00. GSK moved -0.54% today. Year to date, GSK is +3.59%; over the trailing twelve months it is +32.24%. Its 52-week range spans $31.72 to $61.70. Analyst consensus is neutral with an average price target of $54.00. Rallies surfaces GSK's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Which politicians traded GSK stock?

Recent politician trading activity in GSK includes disclosures from Lisa McClain, Robert B. Aderholt, Bruce Westerman, Bruce Westerman, and Marjorie Taylor Greene. Rallies tracks purchase and sale disclosures, transaction dates, owners, reported amounts, and post-trade performance context.

GSK Key Metrics

Key financial metrics for GSK
Metric	Value
Price	$50.83
Market Cap	$100.90B
P/E Ratio	0.00
EPS	$0.00
Dividend Yield	0.46%
52-Week High	$61.70
52-Week Low	$31.72
Volume	2.56M
Avg Volume	0
Revenue (TTM)	$0
Net Income	$0
Gross Margin	0.00%

Congressional Trades in GSK

Lisa McClain purchase GSK on Aug 4, 2025 (amount: $15.00K) for Spouse.
Robert B. Aderholt sale GSK on Jul 28, 2025 (amount: $15.00K).
Bruce Westerman sale GSK on Apr 21, 2025 (amount: $15.00K).
Bruce Westerman purchase GSK on Mar 3, 2025 (amount: $15.00K).
Marjorie Taylor Greene purchase GSK on Nov 25, 2024 (amount: $15.00K).

Latest GSK News

GT Biopharma Doses First GTB-5550 Patient, Intensifying B7-H3 Race with GSK — May 18, 2026
GSK Q1 Revenues Increase 5% to £7.6 Billion; Shingrix Up 20% — Apr 30, 2026
GSK slides 3% after Q1 release as outlook focus and legal items weigh — Apr 29, 2026
GSK Q1 Net Income $2.34B, Revenue $10.28B and Reaffirms 2026 Guidance — Apr 29, 2026
GSK jumps as EMA starts bepirovirsen review; dividend payment due April 9 — Apr 8, 2026

GSK Analyst Consensus

1 analysts cover GSK: 0 strong buy, 0 buy, 1 hold, 0 sell, 0 strong sell. Consensus rating is neutral. Average price target: $54.00.

Common questions about GSK

Which politicians traded GSK stock?: Recent politician trading activity in GSK includes disclosures from Lisa McClain, Robert B. Aderholt, Bruce Westerman, Bruce Westerman, and Marjorie Taylor Greene. Rallies tracks purchase and sale disclosures, transaction dates, owners, reported amounts, and post-trade performance context.
Does Rallies track congressional trades in GSK?: Yes. Rallies tracks politician and congressional stock disclosures for GSK, including reported purchases, sales, dates, owners, and trade amounts when available.
Is GSK research on Rallies investment advice?: No. Rallies provides research, data, and educational context for GSK. It does not provide personalized investment advice.